Artery Disease

Cardiovascular

Prevalence

5.0 / 100K

22 drugs in development·21 companies·1 clinical trial

Drug Pipeline by Phase

Approved(6)

Drug	Company
amlodipine	OXFORD IMMUNOTEC GLOBAL PLC (OXFD)
ammonia n 13	BRIGHT MINDS BIOSCIENCES INC. (DRUG)
fludeoxyglucose f18	BRIGHT MINDS BIOSCIENCES INC. (DRUG)
isosorbide mono	EXELIXIS, INC. (EXEL)
nitroglycerin	DR REDDYS LABORATORIES LTD (RDY)
technetium tc 99m sestamibi	Cardinal Health Inc. (CAH)

Phase 3(5)

Drug	Company
generx	Gene Biotherapeutics, Inc. (CRXM)
human acellular vessel	Humacyte Inc. (HUMA)
plx-pad	Pluri Inc. (PLUR)
virtue sab	Orchestra BioMed Holdings Inc. (OBIO)
xtr004	SPRING PHARMACEUTICAL GROUP, INC. (CYIG)

Phase 2(5)

Drug	Company
aroxxen	PRF Technologies Ltd. (PRFX)
Aroxxen	Crinetics Pharmaceuticals, Inc. (CRNX)
jan101	ALT5 Sigma Corp (ALTS)
regn9933	REGENERON PHARMACEUTICALS, INC. (REGN)
selatogrel	Innovation Pharmaceuticals Inc. (IPIX)

Phase 1(2)

Drug	Company
selatogrel	Viatris Inc (VTRS)
VERVE-102	Travere Therapeutics, Inc. (TVTX)

Preclinical(1)

Drug	Company
electroceuticals therapeutic devices	ENDONOVO THERAPEUTICS, INC. (ENDV)

Phase 4(3)

Drug	Company
High dose potent statin	UNITED THERAPEUTICS Corp (UTHR)
High dose potent statin	CYTOKINETICS INC (CYTK)
prasugrel or ticagrelor	Cidara Therapeutics, Inc. (CDTX)

BioSniper tracks 22 drugs in development for Artery Disease across 21 companies.

There are 1 clinical trial targeting Artery Disease tracked by BioSniper.

The estimated prevalence of Artery Disease is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.